Presenting at the Society for Vascular Medicine (SVM) this year was truly special for three key reasons.

First, it marked my debut at a conference dedicated solely to vascular medicine. It reflects how our healthcare community is now recognizing the prevalence of vascular disease and the importance of having a society dedicated to its study and treatment.

Secondly, I had the opportunity to speak on a crucial but often underdiagnosed and under recognized topic—Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) (blood clots in the legs, which can travel to the lungs and be fatal) and deserves much more attention in the medical field. It was a privilege to moderate a panel alongside passionate experts like Dr. Valle and Dr. Satwah, as we discussed how we can better manage these conditions. 

Finally, the experience was bittersweet because it marked the end of our time as speaker consultants for the Johnson & Johnson division of Xarelto, which has since closed. Rivaroxaban (fondly known as "Riva") has been a life-saving medication in the treatment of DVT and PE, supported by multiple trials demonstrating its effectiveness. The friendships and professional relationships I’ve built with the team—reps, MSLs, managers, and directors—have been incredibly meaningful. Together, we’ve educated countless healthcare providers, physicians, and nurses about this important treatment.

I want to extend my heartfelt thanks to all of you. It has been an incredible journey, and I hope our paths cross again in the future.

#DVT #PE #SVM #vascularsurgerybuffalo